Within Onehealthdrugs we strive to make optimal selection of new drug candidates against vector borne diseases to ensure potency with a minimal environmental impact. In the transition from in vitro to in vivo evaluation we adhere to and advocate for the 3R principle (Replacement, Reduction and Refinement). This joint symposium of the Innovation Centre 3Rs (IC-3Rs), together with RE-Place and the European Horizon 2020 funded TWINALT consortium, will be an opportunity to obtain latest insights into the most advanced 3R-alternative models. This is a strong added value for anyone working with laboratory animals.

https://joint3rsymposium.org/

Highlight persspective from the 3RS meeting

On 26th October there is a free RE-Place webinar. A webinar that would be of interest for our network for the 3R-principle – replacement. Especially the first lecture would be of interest: fish skin models for host-pathogen interactions in the skin.

Inscription is through this link.

 

Maaike Vercauteren, who will present the two-chamber skin explant model developed to study skin diseases in marine fishes, obtained her master degree in Biology. She continued her scientific career as a PhD student at the Faculty of Veterinary Medicine (Ghent University) focusing on the etiology of skin ulcerations in flatfish in the Belgian Part of the North Sea. Currently, she works as a postdoc focusing on the environmental and human health effects of microplastic pollution. Within her PhD project, she developed an innovative alternative method to study pathogen-host interactions in skin diseases. This could be a promising tool providing a valuable alternative for in vivo experiments using skin of marine fish.

Ingrid Vernemmen graduated as a veterinarian at the Faculty of Veterinary Medicine of Ghent University, Belgium in 2019. Subsequently she joined the Equine Cardioteam at Ghent University, where she conducts her PhD research on the use of echocardiography in electrophysiological and interventional procedures in horses, funded by the Research Foundation of Flanders. In addition, she participates in clinical activities concerning the diagnosis and treatment of horses with cardiac disease. Her main interests are echocardiography, electrophysiology and interventional cardiology. Her presentation will cover an ‘Ultrasound compatible 3D model of the equine heart’.

COST
What is COST?

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. The COST ACTIONS help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.

OneHealthdrugs CA21111
Title:

One Health drugs against parasitic vector borne diseases in Europe and beyond

Acronym:

OneHealthdrugs

Start date of the Action:

24/10/2022

End date of the Action:

23/10/2026

CSO approval date:

27/05/2022

Memorandum of Understanding (MoU)

Download file

Contact Points
Chair:

Maria Paola Costi

Vice-Chair:

Anabela Cordeiro da Silva

COST staff

Scientific Officer:
Lucia Forzi
Administrative Officer:
Nathalie Warenghien

Administrative Team

Maria Cristina Notarsanto
Maria Esposito and Laura Leonardi